Takeda announced that zasocitinib met co‑primary and key secondary endpoints in two Phase 3 psoriasis trials, delivering superiority against placebo and Amgen’s Otezla on established disease‑severity measures. The drug, acquired from Nimbus Therapeutics in a multibillion‑dollar deal, is positioned for regulatory submissions in fiscal 2026 and is being evaluated across other immune‑mediated indications. Takeda said the safety profile was consistent with expected class effects, noting common adverse events such as respiratory infections and acne. TYK2 inhibitors are oral small molecules targeting intracellular signaling; success here intensifies competition among oral alternatives to injectable biologics.